These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1836100)

  • 41. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.
    Sharpe N; Murphy J; Smith H; Hannan S
    Lancet; 1988 Feb; 1(8580):255-9. PubMed ID: 2893080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction.
    Schulman SP; Weiss JL; Becker LC; Guerci AD; Shapiro EP; Chandra NC; Siu C; Flaherty JT; Coombs V; Taube JC
    Am J Cardiol; 1995 Oct; 76(11):764-70. PubMed ID: 7572651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postmyocardial infarction patients: experience from the SAVE trial.
    Connors KF; Lamas GA
    Am J Crit Care; 1995 Jan; 4(1):23-8. PubMed ID: 7894551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experiences with ACE inhibitors early after acute myocardial infarction. Rationale and design of the German Multicenter Study on the Effects of Captopril on Cardiopulmonary Exercise parameters post myocardial infarction (ECCE).
    Kleber FX; Reindl I; Wenzel M; Rodewyk P; Beil S; Kosloswki B; Doering W; Sabin GV; Hinzmann S; Winter UJ
    Herz; 1993 Dec; 18 Suppl 1():424-9. PubMed ID: 8125422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
    Mazzotta G; Vecchio C
    G Ital Cardiol; 1994 Jan; 24(1):59-70. PubMed ID: 8200499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
    Dill T; Schächinger V; Rolf A; Möllmann S; Thiele H; Tillmanns H; Assmus B; Dimmeler S; Zeiher AM; Hamm C
    Am Heart J; 2009 Mar; 157(3):541-7. PubMed ID: 19249426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of intervention with losartan or captopril in acute myocardial infarction.
    Spinar J; Vitovec J; Spinarova L; Pluhacek L; Fischerova B; Toman J
    Eur J Heart Fail; 2000 Mar; 2(1):91-100. PubMed ID: 10742708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of life among patients post-myocardial infarction at baseline in the Survival and Ventricular Enlargement (SAVE) trial.
    Gorkin L; Follick MJ; Geltman E; Hamm P; Sollano J; Sylvia S; Jacobson K; Jacobson MJ; Cochrane BS; Sussex B
    Qual Life Res; 1994 Apr; 3(2):111-9. PubMed ID: 8044157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
    Moyé LA; Pfeffer MA; Wun CC; Davis BR; Geltman E; Hayes D; Farnham DJ; Randall OS; Dinh H; Arnold JM
    Eur Heart J; 1994 May; 15 Suppl B():2-8; discussion 26-30. PubMed ID: 8076658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of early use of captopril on haemodynamics and short-term ventricular remodelling in acute anterior myocardial infarction.
    Galcera-Tomas J; Nuño de la Rosa JA; Torres-Martinez G; Rodriguez-Garcia P; Castillo-Soria FJ; Canton-Martinez A; Campos-Peris JV; Pico-Aracil F; Ruiz-Ros JA; Ruiperez-Abizanda JA
    Eur Heart J; 1993 Feb; 14(2):259-66. PubMed ID: 8449203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial.
    Alzahrani T; Tiu J; Panjrath G; Solomon A
    Ther Adv Cardiovasc Dis; 2018 Dec; 12(12):351-359. PubMed ID: 30442080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the tissue affinity of ACE inhibitors of relevance for the remodeling of the left ventricular wall following myocardial infarction? Estimations with cine magnetic resonance imaging.
    Konermann M; Sanner BM; Altmann C; Laschewski F; Rawert B; Trappe HJ
    Cardiology; 2000; 94(3):179-87. PubMed ID: 11279324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The extent of regional wall motion abnormalities identifies patients at risk of extensive left ventricular remodeling: implications for the design of post myocardial infarction trials.
    Zanolla L; Marino P; Golia G; Anselmi M; Zardini P; Borghi C; Ambrosioni E
    G Ital Cardiol; 1999 Jan; 29(1):20-6. PubMed ID: 9987043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design of a randomized, placebo-controlled multicenter trial on the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction. Transdermal Nitroglycerin Investigators Group.
    Pratt CM; Mahmarian JJ; Morales-Ballejo H; Casareto R; Moyé LA
    Am J Cardiol; 1998 Mar; 81(6):719-24. PubMed ID: 9527081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
    Lamas GA; Pfeffer MA; Hamm P; Wertheimer J; Rouleau JL; Braunwald E
    N Engl J Med; 1992 Jul; 327(4):241-7. PubMed ID: 1535419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
    Jang IK; Pettigrew V; Picard MH; Kowey PR; Demmel V; Zile MR; Tatsuno J; Wackers FJ; Hibberd M
    J Thromb Thrombolysis; 2005 Dec; 20(3):147-53. PubMed ID: 16261287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    Yusuf S
    Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.
    Pfeffer MA
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):106S-111S. PubMed ID: 7818835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.